Structure Therapeutics is a clinical-stage biopharmaceutical company designing oral small-molecule drugs, with a primary focus on obesity and related metabolic disease. Its pipeline targets G protein-coupled receptors (GPCRs), including an oral GLP-1 receptor agonist (aleniglipron / GSBR-1290) and follow-on candidates. The approach aims to offer scalable pill-based alternatives to injectable peptide therapies for large chronic-disease populations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -46.8 | — |
| Q2 2025 | 0 | — | -61.7 | — |
| Q3 2025 | 0 | — | -65.7 | — |
| Q4 2025 | 0 | — | 33 | — |
| Q1 2026 | 0 | — | -76 | — |
| Q2 2026 | 0 | — | -106.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Innoviva, Inc. (INVA), Dorchester Minerals, L.P. (DMLP), Azenta, Inc. (AZTA), COMPASS Pathways plc (CMPS), Mega Fortune Company Limited (MGRT), Korsana Biosciences, Inc. (KRSA)